BioSpace News Archive

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Ryvex, LLC (www.ryvex.net) in partnership with SD Biosensor (www.sdbiosensor.com) have donated over 20,000 rapid Antigen tests to the OECS member states and Barbados

- Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints of North Star Ambulatory Assessments (NSAA), 6-minute walk test (6MWT), pulmonary function tests (PFTs), and clinically validated patient reported outcome measures (PROMs) -

Biohaven Pharmaceutical Holding Company Ltd., a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting neurological diseases, including rare disorders, announced that it has commenced an underwritten public offering of $200 million of its common shares.

Sotera Health Company (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share. All 25,000,000 shares are being offered by selling stockholders

Trxade Group, Inc. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States, will release financial results for the fourth quarter and fiscal year ended December 31, 2020, after market close on March 29, 2021.

Announced Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia Interim Analysis Results from Second Confirmatory Phase 3 Study, RALLY, Expected in Third Quarter 2021: Interim Cohort Enrolled Efficacy Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800, Expected in First Quarter 2021

SuperTrans Medical has announced the appointment of three Australian companies to play pivotal roles in an upcoming clinical drug trial that offers new hope in the plight against antimicrobial resistance (AMR), which the World Health Organisation (WHO) describes as a ‘silent pandemic’ and one of the biggest threats to global health.

ViewRay, Inc. (Nasdaq: VRAY) (“the Company”) today announced that Shahriar Matin, Chief Operating Officer, will leave the Company effective March 31, 2021.

The St. Baldrick’s Foundation, the largest non-government funder of childhood cancer research grants, has granted three St. Baldrick’s Fellow Awards totaling more than $573,000 to institutions across the country.